Ryvu Therapeutics S.A. (FRA:9Y4)

Ryvu Therapeutics Statistics

Total Valuation

FRA:9Y4 has a market cap or net worth of EUR 153.61 million. The enterprise value is 143.83 million.

Market Cap	153.61M
Enterprise Value	143.83M

Important Dates

The last earnings date was Thursday, November 20, 2025.

Earnings Date	Nov 20, 2025
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	19.07M
Shares Outstanding	n/a
Shares Change (YoY)	-0.00%
Shares Change (QoQ)	-17.09%
Owned by Insiders (%)	23.59%
Owned by Institutions (%)	47.16%
Float	17.67M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	7.25
PB Ratio	9.20
P/TBV Ratio	10.21
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	-5.17
EV / Sales	6.73
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-5.27

Financial Position

The company has a current ratio of 2.27, with a Debt / Equity ratio of 1.34.

Current Ratio	2.27
Quick Ratio	2.16
Debt / Equity	1.34
Debt / EBITDA	n/a
Debt / FCF	-0.82
Interest Coverage	-14.53

Financial Efficiency

Return on equity (ROE) is -95.35% and return on invested capital (ROIC) is -35.81%.

Return on Equity (ROE)	-95.35%
Return on Assets (ROA)	-23.12%
Return on Invested Capital (ROIC)	-35.81%
Return on Capital Employed (ROCE)	-66.30%
Revenue Per Employee	64,597
Profits Per Employee	-84,805
Employee Count	328
Asset Turnover	0.27
Inventory Turnover	10.02

Taxes

In the past 12 months, FRA:9Y4 has paid 40,543 in taxes.

Income Tax	40,543
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -46.75% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	-46.75%
50-Day Moving Average	5.98
200-Day Moving Average	6.43
Relative Strength Index (RSI)	64.34
Average Volume (20 Days)	8

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, FRA:9Y4 had revenue of EUR 21.19 million and -27.82 million in losses. Loss per share was -1.20.

Revenue	21.19M
Gross Profit	17.30M
Operating Income	-28.54M
Pretax Income	-27.78M
Net Income	-27.82M
EBITDA	-26.24M
EBIT	-28.54M
Loss Per Share	-1.20

Balance Sheet

The company has 32.00 million in cash and 22.31 million in debt, giving a net cash position of 9.69 million.

Cash & Cash Equivalents	32.00M
Total Debt	22.31M
Net Cash	9.69M
Net Cash Per Share	n/a
Equity (Book Value)	16.69M
Book Value Per Share	0.72
Working Capital	21.32M

Cash Flow

In the last 12 months, operating cash flow was -26.70 million and capital expenditures -567,372, giving a free cash flow of -27.27 million.

Operating Cash Flow	-26.70M
Capital Expenditures	-567,372
Free Cash Flow	-27.27M
FCF Per Share	n/a

Margins

Gross margin is 81.66%, with operating and profit margins of -134.69% and -131.28%.

Gross Margin	81.66%
Operating Margin	-134.69%
Pretax Margin	-131.09%
Profit Margin	-131.28%
EBITDA Margin	-123.83%
EBIT Margin	-134.69%
FCF Margin	n/a

Dividends & Yields

FRA:9Y4 does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	0.00%
Shareholder Yield	0.00%
Earnings Yield	-18.11%
FCF Yield	-17.75%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

FRA:9Y4 has an Altman Z-Score of 0.64 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	0.64
Piotroski F-Score	4